Shares of Harmony Biosciences Holdings, Inc. (HRMY) have gained 8.3% over the past four weeks to close the last trading session at $36.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $50.80 indicates a potential upside of 39.5%.The mean estimate comprises 10 short-term price targets with a standard deviation of $13.43. While the lowest estimate of $28 indicates a 23.1% decli ...